LONDON--AstraZeneca PLC (AZN.LN) said Monday that the phase 3 trial of treatment drug Lynparza has met its primary endpoint.

The pharmaceutical company said the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival for patients treated with Lynparza tablets, compared to chemotherapy.

 

Write to Tapan Panchal at tapan.panchal@wsj.com

 

(END) Dow Jones Newswires

June 05, 2017 02:32 ET (06:32 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more AstraZeneca Charts.